Tyme Technologies Inc - Company Profile
Powered by 
All the data and insights you need on Tyme Technologies Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Tyme Technologies Inc Strategy Report
- Understand Tyme Technologies Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Tyme Technologies Inc (Tyme) is a biotechnology company that discovers and develops cancer metabolism-based therapies to treat solid tumors and hematologic cancer. The company’s lead product candidate is SM-88, an oral investigational modified tyrosine derivative for pancreatic, prostate, sarcomas, and breast cancer; TYME-18, cancer metabolism-based investigational therapy for anti-viral and solid tumors. Its therapeutic intervention is designed to compromise cancer’s cellular defences and exploits its innate metabolic weaknesses. Tyme is also investigating TYME-19, a synthetic bile acid for treating SARS-CoV-2 (COVID-19). Tyme is headquartered in Bedminster, New Jersey, the US.
Headquarters
United States of America
Address
1 Pluckemin Way - Suite 103, Bedminster, New Jersey, 07921
Website
www.tymeinc.com
Telephone
1 212 4612315
No of Employees
13
Industry
Pharmaceuticals and Healthcare
Tyme Technologies Inc premium industry data and analytics
Products and Services
| Products |
|---|
| SM-88 - Pancreatic, Prostate |
| Sarcomas and Breast cancer |
| TYME-18 - Anti-Viral and Solid Tumors |
Competitor Comparison
| Key Parameters | Tyme Technologies Inc | Celgene Corp | EOM Pharmaceuticals Holdings Inc | Moleculin Biotech Inc | Tavros Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Bedminster | Summit | Westlake Village | Houston | Durham |
| State/Province | New Jersey | New Jersey | California | Texas | North Carolina |
| No. of Employees | 13 | - | 3 | 15 | - |
| Entity Type | Private | Private | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Douglas A. Michels | Chairman | Executive Board | 2022 | 65 |
| Steven Hoffman | Chairman; Chief Science Officer | Executive Board | - | 59 |
| Richard Cunningham | Chief Executive Officer; Director | Executive Board | 2020 | 51 |
| James Biehl | Chief Legal Officer; Secretary | Senior Management | - | 55 |
| Shabnam Stanicky | Clinical Operations Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer